您的购物车当前为空
别名 斯巴达珠单抗, Spartalizumab(anti-PD-1), PDR001
Spartalizumab (PDR001) 是一种人源化的免疫球蛋白 4 单克隆抗体,在低浓度下选择性与 PD-1结合显示出较高活性。Spartalizumab 阻断与 PD-L1 和 PD-L2 的相互作用,可用于研究甲状腺未分化癌 (ATC)。

为众多的药物研发团队赋能,
让新药发现更简单!
Spartalizumab (PDR001) 是一种人源化的免疫球蛋白 4 单克隆抗体,在低浓度下选择性与 PD-1结合显示出较高活性。Spartalizumab 阻断与 PD-L1 和 PD-L2 的相互作用,可用于研究甲状腺未分化癌 (ATC)。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 1,490 | In Stock | |
| 5 mg | ¥ 4,290 | In Stock | |
| 10 mg | ¥ 5,970 | In Stock | |
| 25 mg | ¥ 8,870 | In Stock | |
| 50 mg | ¥ 12,200 | In Stock |
Spartalizumab 相关产品
| 产品描述 | Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that selectively binds to PD-1 at low concentrations and shows high activity. Spartalizumab blocks the interaction with PD-L1 and PD-L2, and can be used to study undifferentiated thyroid cancer (ATC). |
| 别名 | 斯巴达珠单抗, Spartalizumab(anti-PD-1), PDR001 |
| 分子量 | 145.74 kDa |
| CAS No. | 1935694-88-4 |
| 颜色 | Transparent |
| 物理性状 | Liquid |
| 存储 | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容